Analysts appeared unfazed by the news that a patient treated with Cabaletta Bio’s autoimmune CAR-T suffered a toxicity complication during a phase 1/2 trial. Cabaletta has been evaluating the CAR-T, ...

The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with ...

Researchers said they identified a particular set of adverse effects in autoimmune disease patients treated with chimeric antigen receptor (CAR) T-cell therapy. The syndrome involves transient ...

Prophylactic itacitinib twice daily significantly reduced the incidence of grade ≥ 2 cytokine release syndrome (CRS) compared with placebo (17.4% vs 56.5%) in patients receiving immune effector cell ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...